President Donald Trump has signed an executive order to expedite the review of certain psychedelic drugs, including ibogaine. During the Oval Office event, Trump was joined by podcaster Joe Rogan, a vocal supporter of ibogaine as a treatment for post-traumatic stress. The order aims to relax restrictions on psychedelics for potential therapeutic uses, with Trump expressing optimism about the impact on mental health.
Why It Matters
The executive order represents a significant shift in the US government’s approach to psychedelics, opening the door for more research and potential medical applications. By directing funding towards states advancing psychedelic drug programs and facilitating human trials, the order signals a growing acceptance of alternative treatments for mental illness. The move also underscores the bipartisan support for exploring psychedelics as a possible solution to various mental health issues, marking a notable departure from traditional drug policy approaches.
Want More Context? 🔎
